ClinicalTrials.gg
RecruitingNCT05579366RAINFOL-01Updated Nov 4, 2026

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

A Phase 1/2 interventional study of Rina-S and Carboplatin in High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer and Primary Peritoneal Carcinoma, sponsored by Genmab. Recruiting at 67 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Genmab · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.
Updated Nov 4, 2026First site in South KoreaPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
952
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 589 studies in Fallopian Tube Neoplasms with a site in United States — 63 open to participants now, 130 under way, 24 of them phase 3. Fallopian Tube Neoplasms · United States.

Planned enrollment
12th of 513
952 · median 40
Started
2022
with 28 others
Phase 1/2
58 of 589
10 open now
Primary completion
2028-12
later than 108 of 129 live
Registered
534th of 589
by date

Among the 589 studies in Fallopian Tube Neoplasms with a site in United States, this one is the 12th largest by planned enrollment of the 513 interventional ones that give a count, is one of 29 that started in 2022, is one of 58 in phase 1/2, reaches primary completion later than 108 of the 129 other live ones, and was the 534th registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 131 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

63 of the 589 studies in Fallopian Tube Neoplasms with a site in United States are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 106 Fallopian Tube Neoplasms studies recruiting now, 88 (83%) set no upper age limit and 10 (9%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 589 studies in Fallopian Tube Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.

Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Read the detailed description

This is a Phase 1/2 study of Rina-S; also known as GEN1184, formerly known as PRO1184, a folate receptor alpha (FRα) targeted antibody-drug conjugate, to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Rina-S in participants with selected locally advanced and/or metastatic solid tumors, including epithelial ovarian cancer, endometrial cancer, breast cancer, non-small cell lung cancer, and mesothelioma.

The study consists of multiple parts:

Part A: monotherapy cohorts

Part B: tumor-specific monotherapy dose-expansion cohorts

Part C: platinum-resistant ovarian cancer (PROC) monotherapy cohort

Part D: combination therapy cohorts

Part E: a monotherapy PROC cohort

Parts F and G: a monotherapy endometrial cancer (EC) cohort

Part H: a monotherapy PROC cohort

Part I: platinum-sensitive ovarian cancer (PSOC) cohort

Part J: a monotherapy PROC cohort

Part K: a monotherapy high-grade ovarian cancer cohort

Part L: a drug-drug interaction substudy

Participants will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, pregnancy, or death.

03

Conditions studied

  • High Grade Epithelial Ovarian Cancer
  • High Grade Serous Ovarian Cancer
  • Primary Peritoneal Carcinoma
  • Fallopian Tube Cancer
  • Endometrial Cancer
  • Non-small Cell Lung Cancer
  • Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
  • Mesothelioma
  • Breast Adenocarcinoma
  • Triple Negative Breast Cancer
  • Hormone Receptor-positive/Her2 Negative Breast Cancer
  • Platinum-resistant Ovarian Cancer (PROC)
  • Platinum Sensitive Ovarian Cancer (PSOC)
  • Primary Refractory Ovarian Cancer
  • Uterine Cancer
  • Cervical Cancer

Keywords

  • antibody-drug conjugate
  • folate receptor alpha
  • folate receptor
  • solid tumor
  • ovarian cancer
  • primary peritoneal carcinoma
  • fallopian tube cancer
  • endometrial cancer
  • non-small cell lung cancer
  • mesothelioma
  • breast cancer
  • triple negative breast cancer
  • hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer
  • topoisomerase I inhibitor
  • PROC
  • epidermal growth factor receptor (EGFR)-mutated NSCLC
  • pMMR
04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A and B:

  • or cytologically confirmed or unresectable solid including ovarian cancer (must have epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, -negative and triple-negative) (Part A), mesothelioma or cervical cancer (Part B).
  • Previously received therapies known to confer clinical benefit.
  • per v1.1 for all tumor types other than pleural mesothelioma which will use v1.1 at baseline.

Part C, E, and H:

Participants must have histologically or cytologically confirmed metastatic or unresectable epithelial ovarian cancer as specified below.

  • High grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (excluding endometrioid, clear cell carcinomas, mucinous, low grade, and those with a sarcomatous or neuroendocrine element)
  • Participants must have received up to 3 . Participants may have had up to to 4 prior lines of therapy are allowed if MIRV is locally approved and was used as the last line of therapy. Participants must have progressed radiographically on or after their most recent line of therapy.
  • Participants must have platinum-resistant ovarian cancer.
  • Participants must have received prior bevacizumab or approved biosimilar.
  • Participants with known or suspected deleterious germline or somatic BRCA mutations (as determined by Food and Drug Administration [FDA]-approved test in a Clinical Laboratory Improvement Amendments [CLIA]-certified laboratory; or locally approved equivalent) and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment.
  • Measurable disease per the RECIST v1.1 at baseline.

Part D:

Cohort D1:

  • Participants must have platinum-sensitive ovarian cancer.
  • Participants must have received 1 to 3 prior lines of therapy.

Cohort D2:

  • Participants must have primary platinum-, platinum-resistant, or platinum-sensitive ovarian cancer.
  • Participants with primary platinum-refractory ovarian cancer must have received ≤2 prior lines of therapy. Primary platinum-refractory ovarian cancer is defined as a lack of response or by progression within 91 days after completing front-line platinum containing therapy.
  • Participants must have received 1 to 3 prior lines of therapy for platinum-resistant ovarian cancer (PROC), and up to 4 prior lines of therapy for platinum-sensitive ovarian cancer (PSOC). Prior treatments may have included bevacizumab, PARP inhibitor, and MIRV.

    • Participants with PSOC must have disease progression on or after maintenance treatment, or at least 6 months (>183 days) or more from the last dose of platinum-based therapy.

Cohort D3:

  • Endometrial cancer (any subtype excluding sarcoma).

Cohort D4:

  • Primary advanced or recurrent endometrial cancer (any subtype excluding sarcoma and neuroendocrine tumors).

Cohort D5

  • Primary advanced or recurrent endometrial cancer (any subtype excluding sarcoma and neuroendocrine tumors).

Part F and G:

  • Participants must have histologically or cytologically confirmed EC.
  • Recurrent progressive EC (any subtype excluding neuroendocrine tumors, carcinosarcoma, or endometrial sarcoma) following prior therapy.
  • Participants must have received 1 to 3 prior lines of therapy, and must have progressed radiographically on or after their most recent line of therapy:
  • Participants must have received prior platinum-based chemotherapy and a programmed death-ligand 1 (PD-[L])1 inhibitor.
  • Participants who progress >12 months after completion of prior or neoadjuvant platinum-based chemotherapy must receive 1 additional cytotoxic systemic treatment prior to enrollment in this study.
  • Hormonal therapy alone (i.e., without chemotherapy) will not be counted as a separate line of therapy.
  • Measurable disease per the RECIST Version 1.1 at baseline.

Part I:

  • Participants must have histologically or cytologically confirmed high grade serous or endometrioid epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer (excluding clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies or low grade/borderline ovarian tumors).
  • Participants must have platinum sensitive ovarian cancer.
  • Measurable disease per the RECIST Version 1.1 at baseline.

Part J:

  • Participants must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element.
  • Measurable disease per the RECIST Version 1.1 at baseline.

Part K:

  • Participants must have histologically or cytologically confirmed metastatic or unresectable ovarian cancer (must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element).
  • Participants must have primary platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer.
  • Measurable disease per the RECIST Version 1.1 at baseline.

Part L:

  • Participants must have a histologically or cytologically confirmed metastatic or unresectable solid malignancy. Participants must have previously received all therapies known to confer clinical benefit (unless ineligible to receive or refused to receive or therapy is unavailable in the region). If a standard-of-care therapy is available that has not been administered, the reason that the therapy is not appropriate must be documented.
  • Participants must either have ovarian cancer (must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element), or
  • NSCLC.
  • Age 18 to 65 years (inclusive).
  • An (ECOG) Performance Status score of 0 or 1.
  • Measurable disease per the RECIST version 1.1 at baseline.

Exclusion criteria

Exclusion Criteria:

  • History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required within the past 2 years, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Prior therapy with a topoisomerase 1 inhibitor-based antibody drug conjugate.

Note: Other protocol-defined inclusion/exclusion may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
952 participants (estimated)

Study arms

  • Experimental
    Part A, B, C, E, F, G, H, I, J and K

    Rina-S monotherapy in Part A and at the recommended dose in Parts B, C, E, F, G, H, I, J and K.

    Drug: Rina-S

  • Experimental
    Part D1

    Rina-S in combination with carboplatin

    Drug: Rina-S · Drug: Carboplatin

  • Experimental
    Part D2 and I

    Rina-S in combination with bevacizumab

    Drug: Rina-S · Drug: Bevacizumab

  • Experimental
    Part D3, D4 and D5

    Rina-S in combination with pembrolizumab

    Drug: Rina-S · Drug: Pembrolizumab

  • Experimental
    Part L

    Rina-S in combination with CYP3A4 inhibitors erythromycin or itraconazole.

    Drug: Rina-S · Drug: Erythromycin · Drug: Itraconazole

Interventions

  • DrugRina-S

    Intravenous infusion of Rina-S

    Also known as: PRO1184, Rinatabart sesutecan, GEN1184

  • Carboplatin intravenous infusion

  • Bevacizumab intravenous infusion

  • Pembrolizumab intravenous infusion

  • DrugErythromycin

    Erythromycin oral administration

  • DrugItraconazole

    Itraconazole oral administration

06

What researchers measure

Primary outcomes

  1. Parts A, B, and D - Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]

    Time frame: Through end of treatment, up to approximately 1 year.

  2. Parts A, and D - Number of Participants with Dose Limiting Toxicity (DLT)

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  3. Parts C, E, F, G, H, I, and J- Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR, Parts C and F) or Investigator (Part E, G, I, and J) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Participants who achieve partial response (PR) or complete response (CR) per RECIST v1.1 criteria.

    Time frame: Through end of treatment, up to approximately 1 year.

  4. Part K (US Participants Only) - Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Findings by Holter

    Time frame: Cycles 1 to 3 (each cycle is 21 days)

  5. Part L - Peak Plasma Concentration (Cmax) of Rina-S

    Measurement of maximum plasma concentration after the administration of Rina-S.\[

    Time frame: Cycles 1 and 2 (each cycle is 21 days)

  6. Part L - Area Under the Plasma Concentration Versus Time Curve (AUC) of Rina-S

    Measurement of AUC after the administration of Rina-S.

    Time frame: Cycles 1 and 2 (each cycle is 21 days)

Secondary outcomes

  1. Parts A, B, and D - Best Overall Response (BOR)

    Participants who achieve CR or PR. Best response as assessed by the investigator per RECIST v1.1 criteria for all tumor types other than pleural mesothelioma which will use modified RECIST (mRECIST) v1.1.

    Time frame: Up to approximately 1 year.

  2. Parts A, B, D, and E - ORR

    Participants who achieve PR or CR per RECIST v1.1 criteria.

    Time frame: Up to approximately 1 year.

  3. Parts A, B, and D - Disease Control Rate (DCR)

    Participants who achieve stable disease, PR or CR per RECIST v1.1 criteria.

    Time frame: Up to approximately 1 year.

  4. Parts A, B, C, D, E, F, G, H, I, and J - Progression-Free Survival (PFS)

    Time from start of treatment to first documented disease progression or death

    Time frame: Through end of treatment, up to approximately 1 year.

  5. Parts C, E, F, G, H, I and J - Overall survival (OS)

    Time from the start of study treatment to the date of death from any cause

    Time frame: Up to approximately 2 years.

  6. Parts A, B, C, D, E, F, G, H, I and J - Duration of Objective Response (DOR)

    Time from the first documentation of an objective tumor response (CR or PR) to the first documented tumor progression or death

    Time frame: From date of enrollment until the date of first documented disease progression or date of study withdrawal, whichever came first, assessed up to 12 months.

  7. Parts A, B, D, and E - Cmax for Rina-S

    Measurement of maximum plasma concentration after the administration of Rina-S.

    Time frame: Through end of treatment, up to approximately 1 year.

  8. Parts A, B, D, and E - AUC for Rina-S

    Measurement of AUC after the administration of Rina-S.

    Time frame: Through end of treatment, up to approximately 1 year.

  9. Parts A, B, D, and E -Time to Reach Cmax (Tmax) for Rina-S

    Time frame: Through end of treatment, up to approximately 1 year

  10. Parts A, B, D, and E - Trough Concentrations (Ctrough) for Rina-S

    Time frame: Through end of treatment, up to approximately 1 year

  11. Parts A, B, D, and E- Apparent Terminal Half-life (t1/2) for Rina-S

    Time frame: Through end of treatment, up to approximately 1 year

  12. Parts C, D, E, H and J - CA-125 Response Determined Using the Gynecologic Cancer Intergroup (GCIG) Criteria

    Time frame: Through end of treatment, up to approximately 1 year

  13. Parts C, E, F, G, H, I, J, K and L - Number of Participants with Type, Incidence, Severity, Seriousness as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0, and Relatedness of Adverse Events (AEs)

    Time frame: Through end of treatment, up to approximately 1 year

  14. Part E - Number of Participants With Antidrug Antibodies (ADA)

    Time frame: Through end of treatment, up to approximately 1 year

  15. Part L - Number of Participants with DLT

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

07

Study locations

67 of 67 sites recruiting
  • USOR HonorHealth
    Phoenix, Arizona 85016, United States
    Recruiting
  • USOR Arizona Oncology Associates
    Tucson, Arizona 85711, United States
    Recruiting
  • University of California Los Angeles Medical Center
    Los Angeles, California 90095, United States
    Recruiting
  • University of California, San Diego; Moores Cancer Center
    San Diego, California 92093, United States
    Recruiting
  • USOR Sansum Clinic
    Santa Barbara, California 93105, United States
    Recruiting
  • Providence Medical Foundation
    Santa Rosa, California 95403, United States
    Recruiting
  • USOR Florida Cancer Specialists South
    Fort Myers, Florida 33908, United States
    Recruiting
  • USOR Florida Cancer Specialists North
    St. Petersburg, Florida 33709, United States
    Recruiting
  • USOR Florida Cancer Specialists East
    West Palm Beach, Florida 33401, United States
    Recruiting
  • Augusta University Georgia Cancer Center
    Augusta, Georgia 30912, United States
    Recruiting
  • University of Kansas Medical Center (KUMC)
    Westwood, Kansas 66205, United States
    Recruiting
  • USOR Maryland Oncology Hematology
    Rockville, Maryland 20850, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
  • Karmanos Cancer Institute
    Detroit, Michigan 48085, United States
    Recruiting
  • START Midwest
    Grand Rapids, Michigan 49503, United States
    Recruiting
  • USOR Minnesota Oncology Hematology
    Maplewood, Minnesota 55109, United States
    Recruiting
  • MD Anderson Cancer Center at Cooper- Two Cooper Plaza
    Camden, New Jersey 08103, United States
    Recruiting
  • Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute
    Columbus, Ohio 43210, United States
    Recruiting
  • University of Oklahoma - Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • USOR Oncology Associates of Oregon, P.C.
    Eugene, Oregon 97401, United States
    Recruiting
  • Compass Oncology - Rose Quarter
    Portland, Oregon 97227, United States
    Recruiting
  • USOR Alliance Cancer Specialist
    Doylestown, Pennsylvania 18901, United States
    Recruiting
  • Allegheny Health Network
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
  • Women and Infants Hospital of Rhode Island
    Providence, Rhode Island 02905, United States
    Recruiting
  • Sarah Cannon Research Institute at Tennessee Oncology
    Nashville, Tennessee 37203, United States
    Recruiting
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
    Recruiting
  • USOR Texas Oncology
    Abilene, Texas 79606, United States
    Recruiting
  • Texas Oncology - Central / South Texas
    Austin, Texas 78758, United States
    Recruiting
  • Mary Crowley Cancer Research
    Dallas, Texas 75521, United States
    Recruiting
  • USOR Texas Oncology
    Fort Worth, Texas 76104, United States
    Recruiting
  • Texas Oncology - Northeast TX
    Tyler, Texas 75702, United States
    Recruiting
  • USOR Texas Oncology Gulf Coast
    Woodland, Texas 77380, United States
    Recruiting
  • START Mountain Region
    West Valley City, Utah 84119, United States
    Recruiting
  • USOR Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
    Recruiting
  • USOR Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
    Recruiting
  • Swedish Cancer Institute
    Everett, Washington 98104, United States
    Recruiting
  • Cancer hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality, China
    Recruiting
  • Fujian Cancer Hospital
    Fujian, China, China
    Recruiting
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangdong, China, China
    Recruiting
  • Second Affiliated Hospital of Zhengzhou University
    Henan, China, China
    Recruiting
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Hubei, China, China
    Recruiting
  • Second Hospital of Shanxi Medical University
    Shanxi, China, China
    Recruiting
  • Shanxi Cancer Hospital
    Shanxi, China, China
    Recruiting
  • Liaoning Cancer Hospital & Institute
    Shengyang, China, China
    Recruiting
  • Tianjin Cancer Hospital
    Tianjin, China, China
    Recruiting
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing Municipality, China
    Recruiting
  • Hunan Cancer Hospital - Phase 1
    Changsha, Hunan, China
    Recruiting
  • Hunan Cancer Hospital - Thoracic Medicine Dept II
    Changsha, Hunan, China
    Recruiting
  • Jiangxi Maternal and Child Health Hospital
    Nanchang, Jiangxi, China
    Recruiting
  • Jilin Cancer Hospital
    Changchun, Jilin, China
    Recruiting
  • Obstetrics & Gynecology Hospital of Fudan University
    Chengdu, Shanghai Municipality, China
    Recruiting
  • Fudan University Shanghai Cancer Center - Gynecologic Oncology
    Shanghai, Shanghai Municipality, China
    Recruiting
  • Fudan University Shanghai Cancer Center- Phase 1
    Shanghai, Shanghai Municipality, China
    Recruiting
  • Shanghai East Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting
  • Sichuan Cancer Hospital
    Shanghai, Sichuan, China
    Recruiting
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
    Recruiting
  • Fukushima Medical University Hospital
    Fukushima, Fukushima, Japan
    Recruiting
  • Gunma Prefectural Cancer Center
    Ōta, Gunma, Japan
    Recruiting
  • Sapporo Medical University Hospital
    Sapporo, Hokkaido, Japan
    Recruiting
  • Hyogo Cancer Center
    Akashi, Hyōgo, Japan
    Recruiting
  • Saitama Medical University-International Medical Center
    Hidaka, Saitama, Japan
    Recruiting
  • Shizuoka Cancer Center
    Nagaizumi-chō, Shizuoka, Japan
    Recruiting
  • Cancer Institute Hospital of JFCR
    Koto, Tokyo, Japan
    Recruiting
  • Keio University Hospital
    Shinjuku-ku, Tokyo, Japan
    Recruiting
  • Yamagata University Hospital
    Yamagata, Yamagata, Japan
    Recruiting
  • Korea Institute of Radiological and Medical Sciences
    Seoul, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2028, 72 months after the start.

Of 37 phase 1/2 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 110. This study's planned 72 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Jul 2027 → Dec 2028 and completion Oct 2027 → Mar 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2022
First posted
Oct 13, 2022
StartActual
Dec 7, 2022
Primary completionEst.
Dec 2028was Jul 2027
CompletionEst.
Mar 2029was Oct 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added, 9 sites removed — first site in South Korea
Show 10 added (8 China, 1 United States, 1 South Korea)
  • Swedish Cancer Institute · Everett, United States
  • Fujian Cancer Hospital · Fujian, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University · Guangdong, China
  • Second Affiliated Hospital of Zhengzhou University · Henan, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology · Hubei, China
  • Second Hospital of Shanxi Medical University · Shanxi, China
  • Shanxi Cancer Hospital · Shanxi, China
  • Liaoning Cancer Hospital & Institute · Shengyang, China
  • Tianjin Cancer Hospital · Tianjin, China
  • Korea Institute of Radiological and Medical Sciences · Seoul, South Korea
Show 9 removed
  • Swedish Cancer Institute · Seattle, United States
  • Fujian Cancer Hospital · Fujian, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University · Guangdong, China
  • Second Affiliated Hospital of Zhengzhou University · Henan, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology · Hubei, China
  • Second Hospital of Shanxi Medical University · Shanxi, China
  • Shanxi Cancer Hospital · Shanxi, China
  • Liaoning Cancer Hospital & Institute · Shengyang, China
  • Tianjin Cancer Hospital · Tianjin, China
across 2 updates, Oct 7, 2026 – Nov 4, 2026
Primary completion
Jul 2027→Dec 2028
Nov 4, 2026
Study completion
Oct 2027→Mar 2029
Nov 4, 2026
Enrollment
884→952
Oct 7, 2026
Eligibility
9 inclusion criteria added
What changed in the criteria
Inclusion criteria
  • AddedCohort D5
  • AddedPrimary advanced or recurrent endometrial cancer (any subtype excluding sarcoma and neuroendocrine tumors).
  • AddedPart L:
  • AddedParticipants must have a histologically or cytologically confirmed metastatic or unresectable solid malignancy. Participants must have previously received all therapies known to confer clinical benefit (unless ineligible to receive or refused to receive or therapy is unavailable in the region). If a standard-of-care therapy is available that has not been administered, the reason that the therapy is not appropriate must be documented.
  • AddedParticipants must either have ovarian cancer (must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element), or
  • AddedNSCLC.
  • AddedAge 18 to 65 years (inclusive).
  • AddedAn Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
  • AddedMeasurable disease per the RECIST version 1.1 at baseline.
Oct 7, 2026
Interventions
Added Drug: Erythromycin·Drug: Itraconazole. Arm changed Part D3 and D4→Part D3, D4 and D5. Arms added: Part L
Oct 7, 2026
Primary outcomes
1 edited, 2 added
What changed in the outcomes
  • EditedParts A, and D - Number of Participants with Dose Limiting Toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days)
  • AddedPart L - Peak Plasma Concentration (Cmax) of Rina-STime frame: Cycles 1 and 2 (each cycle is 21 days)
  • AddedPart L - Area Under the Plasma Concentration Versus Time Curve (AUC) of Rina-STime frame: Cycles 1 and 2 (each cycle is 21 days)
Oct 7, 2026
Secondary outcomes
4 edited, 1 added
What changed in the outcomes
  • EditedParts A, B, C, D, E, F, G, H, I and J - Duration of Objective Response (DOR)Time frame: From date of enrollment until the date of first documented disease progression or date of study withdrawal, whichever came first, assessed up to 12 months.
  • EditedParts A, B, D, and E - Peak Plasma Concentration (Cmax) for Rina-STime frame: Through end of treatment, up to approximately 1 year.
  • EditedParts A, B, D, and E - Area Under the Plasma Concentration Versus Time Curve (AUC) for Rina-STime frame: Through end of treatment, up to approximately 1 year.
  • EditedParts C, E, F, G, H, I, J, K and KL - Number of Participants with Type, Incidence, Severity, Seriousness as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0, and Relatedness of Adverse Events (AEs)Time frame: Through end of treatment, up to approximately 1 year
  • AddedPart L - Number of Participants with DLTTime frame: At the end of Cycle 1 (each cycle is 21 days)
Oct 7, 2026
Show all 2 updates
  1. Nov 4, 2026
    1 site added — first site in South Korea
    Show site
    • Korea Institute of Radiological and Medical Sciences · Seoul, South Korea
    Primary completion Jul 2027→Dec 2028
    Study completion Oct 2027→Mar 2029
  2. Oct 7, 2026
    9 sites added, 9 sites removed
    Show 9 added (8 China, 1 United States)
    • Swedish Cancer Institute · Everett, United States
    • Fujian Cancer Hospital · Fujian, China
    • Sun Yat-sen Memorial Hospital, Sun Yat-sen University · Guangdong, China
    • Second Affiliated Hospital of Zhengzhou University · Henan, China
    • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology · Hubei, China
    • Second Hospital of Shanxi Medical University · Shanxi, China
    • Shanxi Cancer Hospital · Shanxi, China
    • Liaoning Cancer Hospital & Institute · Shengyang, China
    • Tianjin Cancer Hospital · Tianjin, China
    Show 9 removed
    • Swedish Cancer Institute · Seattle, United States
    • Fujian Cancer Hospital · Fujian, China
    • Sun Yat-sen Memorial Hospital, Sun Yat-sen University · Guangdong, China
    • Second Affiliated Hospital of Zhengzhou University · Henan, China
    • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology · Hubei, China
    • Second Hospital of Shanxi Medical University · Shanxi, China
    • Shanxi Cancer Hospital · Shanxi, China
    • Liaoning Cancer Hospital & Institute · Shengyang, China
    • Tianjin Cancer Hospital · Tianjin, China
    Enrollment 884→952
    Eligibility 9 inclusion criteria added
    What changed in the criteria
    Inclusion criteria
    • AddedCohort D5
    • AddedPrimary advanced or recurrent endometrial cancer (any subtype excluding sarcoma and neuroendocrine tumors).
    • AddedPart L:
    • AddedParticipants must have a histologically or cytologically confirmed metastatic or unresectable solid malignancy. Participants must have previously received all therapies known to confer clinical benefit (unless ineligible to receive or refused to receive or therapy is unavailable in the region). If a standard-of-care therapy is available that has not been administered, the reason that the therapy is not appropriate must be documented.
    • AddedParticipants must either have ovarian cancer (must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element), or
    • AddedNSCLC.
    • AddedAge 18 to 65 years (inclusive).
    • AddedAn Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
    • AddedMeasurable disease per the RECIST version 1.1 at baseline.
    Primary outcomes 1 edited, 2 added
    What changed in the outcomes
    • EditedParts A, and D - Number of Participants with Dose Limiting Toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days)
    • AddedPart L - Peak Plasma Concentration (Cmax) of Rina-STime frame: Cycles 1 and 2 (each cycle is 21 days)
    • AddedPart L - Area Under the Plasma Concentration Versus Time Curve (AUC) of Rina-STime frame: Cycles 1 and 2 (each cycle is 21 days)
    Secondary outcomes 4 edited, 1 added
    What changed in the outcomes
    • EditedParts A, B, C, D, E, F, G, H, I and J - Duration of Objective Response (DOR)Time frame: From date of enrollment until the date of first documented disease progression or date of study withdrawal, whichever came first, assessed up to 12 months.
    • EditedParts A, B, D, and E - Peak Plasma Concentration (Cmax) for Rina-STime frame: Through end of treatment, up to approximately 1 year.
    • EditedParts A, B, D, and E - Area Under the Plasma Concentration Versus Time Curve (AUC) for Rina-STime frame: Through end of treatment, up to approximately 1 year.
    • EditedParts C, E, F, G, H, I, J, K and KL - Number of Participants with Type, Incidence, Severity, Seriousness as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0, and Relatedness of Adverse Events (AEs)Time frame: Through end of treatment, up to approximately 1 year
    • AddedPart L - Number of Participants with DLTTime frame: At the end of Cycle 1 (each cycle is 21 days)
    Interventions Added Drug: Erythromycin·Drug: Itraconazole. Arm changed Part D3 and D4→Part D3, D4 and D5. Arms added: Part L
    + 4 other changes: verification date, description, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05579366
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Oct 13, 2022
Start date
Dec 7, 2022
Primary completion
Dec 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Genmab Trial Information
Contact
clinicaltrials@genmab.com
+4570202728
Study Official
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rinatabart sesutecan

Start the discussion